<?xml version="1.0"?><rdf:RDF xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:edm="http://www.europeana.eu/schemas/edm/" xmlns:wgs84_pos="http://www.w3.org/2003/01/geo/wgs84_pos" xmlns:foaf="http://xmlns.com/foaf/0.1/" xmlns:rdaGr2="http://rdvocab.info/ElementsGr2" xmlns:oai="http://www.openarchives.org/OAI/2.0/" xmlns:owl="http://www.w3.org/2002/07/owl#" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:ore="http://www.openarchives.org/ore/terms/" xmlns:skos="http://www.w3.org/2004/02/skos/core#" xmlns:dcterms="http://purl.org/dc/terms/"><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-K0TJLOQE/7e758b46-bcf1-4ffd-bcae-0ffbe35e822b/HTML"><dcterms:extent>31 KB</dcterms:extent></edm:WebResource><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-K0TJLOQE/82054d1b-6e89-42d9-bd2f-dcaa6de9064b/PDF"><dcterms:extent>161 KB</dcterms:extent></edm:WebResource><edm:WebResource rdf:about="http://www.dlib.si/stream/URN:NBN:SI:doc-K0TJLOQE/9ee27b49-594a-4fb4-924c-049fbf94db41/TEXT"><dcterms:extent>30 KB</dcterms:extent></edm:WebResource><edm:TimeSpan rdf:about="1929-2026"><edm:begin xml:lang="en">1929</edm:begin><edm:end xml:lang="en">2026</edm:end></edm:TimeSpan><edm:ProvidedCHO rdf:about="URN:NBN:SI:doc-K0TJLOQE"><dcterms:isPartOf rdf:resource="https://www.dlib.si/details/urn:nbn:si:spr-a30mfzkp" /><dcterms:issued>2005</dcterms:issued><dc:creator>Mavri, Alenka</dc:creator><dc:format xml:lang="sl">številka:6</dc:format><dc:format xml:lang="sl">letnik:74</dc:format><dc:format xml:lang="sl">str. 375-379</dc:format><dc:identifier>ISSN:1318-0347</dc:identifier><dc:identifier>COBISSID:19576537</dc:identifier><dc:identifier>URN:URN:NBN:SI:doc-K0TJLOQE</dc:identifier><dc:language>sl</dc:language><dc:publisher xml:lang="sl">Slovensko zdravniško društvo</dc:publisher><dcterms:isPartOf xml:lang="sl">Zdravniški vestnik</dcterms:isPartOf><dc:subject xml:lang="sl">ateroskleroza</dc:subject><dc:subject xml:lang="en">Atherosclerosis</dc:subject><dc:subject xml:lang="sl">Debelost</dc:subject><dc:subject xml:lang="en">Diabetes Mellitus, Non-Insulin-Dependent</dc:subject><dc:subject xml:lang="sl">Hiperinzulinemija</dc:subject><dc:subject xml:lang="sl">Hiperlipidemija</dc:subject><dc:subject xml:lang="sl">Hipertenzija</dc:subject><dc:subject xml:lang="en">Hyperinsulinemia</dc:subject><dc:subject xml:lang="en">Hyperlipidemia</dc:subject><dc:subject xml:lang="en">Hypertension</dc:subject><dc:subject xml:lang="en">insulin</dc:subject><dc:subject xml:lang="en">Insulin Resistance</dc:subject><dc:subject xml:lang="sl">Insulinska rezistenca</dc:subject><dc:subject xml:lang="sl">metabolizem</dc:subject><dc:subject xml:lang="en">Obesity</dc:subject><dc:subject xml:lang="en">Plasminogen Activator Inhibitor 1</dc:subject><dc:subject xml:lang="sl">Plazminogen aktivator, inhibitor 1</dc:subject><dc:subject xml:lang="sl">presnovne motnje</dc:subject><dc:subject xml:lang="sl">Sladkorna bolezen, ne-inzulin-odvisna</dc:subject><dcterms:temporal rdf:resource="1929-2026" /><dc:title xml:lang="sl">Povezava med metabolnim sindromom, inhibitorjem aktivatorja plazminogena (PAI-1) in aterosklerozo| Metabolic syndrome, plasminogen activator inhibitor (PAI-1) and atherosclerosis|</dc:title><dc:description xml:lang="sl">Background. Metabolic syndrome is associated with high cardiovascular morbidity and mortality and its increasing prevalence is becoming one of the major health problems. Atherothrombotic process is accelerated in the metabolic syndrome and this is attributed to metabolic abnormalities, hypofibrinolysis due to increased plasma PAI-1 levels, and inflammation. Proinflammatory cytokines, particularly tumour necrosis factor-a may have an important role in PAI-1 overexpresion in the adipose tissue. PAI-1 might be involved in the etiopathogenesis of obesity and insulin resistance. Conclusions. To understand a complex interplay between metabolic syndrome, PAi-1 and atherosclerosis further studies are needed</dc:description><dc:description xml:lang="sl">Izhodišča. Prevalenca metabolnega sindroma v razvitem svetu strmo narašča, karje velik zdravstveni problem, saj metabolni sindrom spremlja visoka stopnjasrčnožilne obolevnosti in umrljivosti. Na pospešen proces aterotrombozepri ljudeh z metabolnim sindromom vplivajo presnovne motnje, hipofibrinoliza zaradi zvečane ravni inhibitorja aktivatorja plazminogena (PAI-1) in kronično subklinično vnetje. Vnetni citokini, predvsem dejavnik tumorske nekroze-a, se vpletajo v uravnavanje tvorbe PAI-1 v maščevju. PAI-1 je lahko eden pomembnejših etiopatogenetskih dejavnikov tako za debelost kot tudi za neodzivnost na insulin. Zaključki. Za dokončno razjasnitev povezav medmetabolnim sindromom, PAI-1 in aterosklerozo bodo potrebne še številne raziskave, predvsem intervencijske</dc:description><edm:type>TEXT</edm:type><dc:type xml:lang="sl">znanstveno časopisje</dc:type><dc:type xml:lang="en">journals</dc:type><dc:type rdf:resource="http://www.wikidata.org/entity/Q361785" /></edm:ProvidedCHO><ore:Aggregation rdf:about="http://www.dlib.si/?URN=URN:NBN:SI:doc-K0TJLOQE"><edm:aggregatedCHO rdf:resource="URN:NBN:SI:doc-K0TJLOQE" /><edm:isShownBy rdf:resource="http://www.dlib.si/stream/URN:NBN:SI:doc-K0TJLOQE/82054d1b-6e89-42d9-bd2f-dcaa6de9064b/PDF" /><edm:rights rdf:resource="http://creativecommons.org/licenses/by-nc/4.0/" /><edm:provider>Slovenian National E-content Aggregator</edm:provider><edm:intermediateProvider xml:lang="en">National and University Library of Slovenia</edm:intermediateProvider><edm:dataProvider xml:lang="sl">Slovensko zdravniško društvo</edm:dataProvider><edm:object rdf:resource="http://www.dlib.si/streamdb/URN:NBN:SI:doc-K0TJLOQE/maxi/edm" /><edm:isShownAt rdf:resource="http://www.dlib.si/details/URN:NBN:SI:doc-K0TJLOQE" /></ore:Aggregation></rdf:RDF>